Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Choueiri, T. K.; Hessel, C.; Halabi, S.; Sanford, B.; Hahn, O.; Michaelson, M. D.; Walsh, M.; Olencki, T.; Picus, J.; Small, E. J.; Dakhil, S.; Scheffold, C.; George, D. J.; Morris, M. J. |
| Abstract Title: | Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx440.032 |
| Language: | English |
| ACCESSION: | WOS:000411324005092 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx440.032 |
| Notes: | Meeting Abstract: LBA38 -- Appears on page 623 of the abstract book -- Source: Wos |
